Liminatus Pharma Inc（LIMN）资讯与事件LIMNLiminatus Pharma Inc

Liminatus Pharma Engages Synex Consulting for IBC101 Development

Liminatus Pharma announced that it has engaged Synex Consulting to support the clinical development of IBC101, the company's CD19xCD22 bivalent CAR-T cell therapy candidate. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma, with Seoul St. Mary's Hospital identified as the lead clinical site. Under the engagement, Synex will provide clinical research services pursuant to a milestone-based program, with payments linked to key clinical development milestones, including patient enrollment, database lock and completion of the clinical study report.

Liminatus Pharma Amends Merger Agreement with InnocsAI, Transaction Valued at Approximately $320M

Liminatus Pharma announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI. The transaction has been re-structured to allow closing prior to obtaining stockholder approval, with closing now expected to occur on July 2, subject to the satisfaction or waiver of customary closing conditions. Under the amended terms of the merger agreement, the equity holders of InnocsAI will receive merger consideration consisting of a combination of Liminatus common stock and newly designated non-voting convertible preferred stock, at an issue price of 20c per common share, representing an aggregate implied transaction value of approximately $320M, together with contingent value rights representing the right to receive 20% of future net proceeds from certain strategic transactions involving the acquired assets. The InnocsAI equity holders will receive shares of Liminatus common stock representing up to the maximum amount issuable without prior stockholder approval under applicable Nasdaq listing rules; and the balance of the merger consideration will consist of shares of newly designated non-voting convertible preferred stock. The non-voting convertible preferred stock will not be convertible into common stock unless and until the company has obtained stockholder approval for the issuance of the underlying common shares to the extent required under applicable Nasdaq listing rules. The merger consideration is expected to be issued following the closing in accordance with the amended terms of the merger agreement and related transaction documents.

Liminatus Pharma Files to Sell 20.69M Shares of Common Stock

Liminatus Pharma files to sell 20.69M shares of common stock for holders